Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic HSCT with Fludarabine/Busulfan/ATG in Older Patients
NCT00806767Phase 2Completed
- Sponsor
- Institut Paoli-Calmettes
- Start
- Mar 2007
- Primary completion
- May 2011
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fludarabine, busulfan, antilymphocyte serum in hematological malignancy, chronic myeloproliferative disorder (MPN), leukemia, lymphoma, multiple myeloma (MM), sponsored by Institut Paoli-Calmettes. Started Mar 2007; status: completed.
02
Drugs
fludarabinebusulfanantilymphocyte serum
03
Conditions
hematological malignancychronic myeloproliferative disorder (MPN)leukemialymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT00806767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00806767.